iBio rises as obesity drug gets first green light for human trial in Australia

iBio

08/04/2026 12:11

** Shares of biotech firm iBio IBIO.O rise 7% to $2.25 premarket

** Co says Australian regulators have cleared first human study of its experimental obesity drug IBIO-600

** Drug targets obesity and aims to preserve muscle while people lose weight - IBIO

** Says IBIO-600 is designed to be used alongside GLP-1 weight-loss drugs, which can cause muscle loss

** Adds early-stage study will test safety and how the drug behaves in overweight and obese adults

** Says animal studies showed gains in lean muscle and reductions in fat; drug could be dosed just a few times a year

** As of last close, IBIO up ~9% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))